Medullary thyroid cancer other diagnostic studies

Medullary thyroid cancer Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Medullary thyroid cancer from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Staging
History and Symptoms
Physical Examination
Laboratory Findings
CT
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Medullary thyroid cancer other diagnostic studies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Medullary thyroid cancer other diagnostic studies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Medullary thyroid cancer other diagnostic studies
CDC on Medullary thyroid cancer other diagnostic studies
Medullary thyroid cancer other diagnostic studies in the news
Blogs on Medullary thyroid cancer other diagnostic studies
Directions to Hospitals Treating Medullary thyroid cancer
Risk calculators and risk factors for Medullary thyroid cancer other diagnostic studies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Key Findings in genetic testing in Medullary Thyroid Cancer

Nuclear imaging

• radioactive iodine: lesions do not concentrate radioactive iodine since the tumour does not arise from thyroid follicular cells

FDG-PET: avid uptake Tl-201: It has been shown to concentrate Thallium-201 5 I-123 MIBG: 30% of MTCs show uptake if the thyroid is blocked with Lugol solution prior to the scan

References

Template:WikiDoc Sources